Showing results (51-60 of 98) with videos related to

Sort By:
Pageof 10
Clinical Pharmacology : Advances and Applications|November 30, 2017
Population pharmacokinetics of pomalidomide in patients with relapsed or refractory multiple myeloma with various degrees of impaired renal functionYan Li, Xiaomin Wang, Edward O'Mara, et al.
Blood Cancer Journal|February 19, 2021
Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of lifeEvangelos Terpos, Joseph Mikhael, Roman Hajek, et al.
British Journal of Haematology|February 8, 2021
Health-related quality of life maintained over time in patients with relapsed or refractory multiple myeloma treated with daratumumab in combination with bortezomib and dexamethasone: results from the phase III CASTOR trialVania Hungria, Meral Beksac, Katja C Weisel, et al.
Leukemia & Lymphoma|June 9, 2016
Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trialsDavid S Siegel, Katja C Weisel, Meletios A Dimopoulos, et al.
Blood Cancer Journal|January 4, 2023
Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myelomaElias K Mai, Stefanie Huhn, Kaya Miah, et al.
Blood Advances|January 19, 2018
Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myelomaMaximilian Merz, Anna Jauch, Thomas Hielscher, et al.
European Journal of Haematology|January 13, 2026
Comparative Effectiveness and Safety of PI-Rd Triplets in Relapsed/Refractory Multiple Myeloma: INSIGHT-MM Data AnalysisNoemi Puig, Xavier Leleu, Hans C Lee, et al.
American Journal of Hematology|July 28, 2025
Practical Guidance on Clinical Management of Belantamab Mafodotin-Associated Ocular EventsEvangelos Terpos, Suzanne Trudel, María-Victoria Mateos, et al.
Expert Opinion on Investigational Drugs|July 14, 2025
Isatuximab for the treatment of multiple myeloma: current clinical advances and future directionsPaul G Richardson, Elisabeth K O'Donnell, Peter O'Gorman, et al.
Blood Cancer Journal|April 1, 2026
Effectiveness of linvoseltamab versus real-world standard-of-care in triple-class-exposed relapsed/refractory multiple myeloma in the United StatesShaji Kumar, Katja C Weisel, Paul Spin, et al.
Pageof 10